The FDA approval addresses acquired endocrine resistance by allowing eligible patients with HR-positive, HER2-negative advanced breast cancer to switch to camizestrant when an ESR1 mutation is detected in...
An updated systematic review of randomized, placebo-controlled trials found that long-term combined and estrogen-only hormone therapy may have different risk-benefit profiles for stroke, breast cancer,...
No HIV acquisitions occurred among 315 cisgender and transgender women receiving long-acting cabotegravir PrEP in the real-world US OPERA Cohort, despite mostly short injection delays.
The FDA approved the norelgestromin and ethinyl estradiol transdermal system (Gwyn Lo, Viatris Inc), a once-weekly combined hormonal contraceptive patch, based on phase 3 data on efficacy, safety, and...
July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
In a cross-sectional questionnaire study of 106 adults with migraine, vomiting-induced migraine pain relief occurred in 54.9% of patients who vomited during attacks, with some reporting pain relief within...
The FDA approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected after...
The FDA approved sacituzumab govitecan-hziy (Trodelvy) as monotherapy, and with pembrolizumab-based therapy, for select adults with previously untreated unresectable locally advanced or metastatic...
ACOG’s 2026 maternal immunization schedule outlines vaccine recommendations before, during, and after pregnancy, including influenza, COVID-19, Tdap, and RSV vaccination.
